The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InIn a move reflecting renewed momentum in the healthcare sector, the ALPS Medical Breakthroughs ETF (SBIO) recorded an exceptional 18.7% return during June. This strong performance was primarily driven by AbbVie's announcement of its acquisition of Apogee Therapeutics in a major deal valued at $10.9 billion. Additionally, positive clinical trial results from Definium and Oruka Therapeutics further bolstered investor confidence and pushed sector stocks higher.
These gains come amid a wave of consolidation in the biotech industry, as giants like AbbVie seek to strengthen their drug pipelines ahead of patent expirations. Compared to broader sector performance, the SBIO ETF outperformed traditional biotech indices due to its focus on companies with drugs in advanced clinical stages. Per market data, ABBV shares stood at $251.07 (at close July 1, 2026), having fluctuated between a low of $247.59 and a high of $251.8 during the session.
Traders should watch for support levels on ABBV near $247.59, its early July low, to gauge the sustainability of this rally. Looking at the economic calendar, upcoming speeches from Fed officials may impact risk appetite in the growth sector, while investors await further updates on the Apogee acquisition timeline as a future catalyst for the industry.